Cargando…
Improvement of the rituximab–induced cell death by potentiation of the store-operated calcium entry in mantle cell lymphoma cell lines
Mantle Cell Lymphoma (MCL) is one of the worst lymphomas with a median overall survival of 3 to 4 years. Even if the use of rituximab was a great step in therapy, patients commonly develop resistance and relapse. New therapies or complement of existing therapies should be developed. Using spectroflu...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6633894/ https://www.ncbi.nlm.nih.gov/pubmed/31320998 http://dx.doi.org/10.18632/oncotarget.27063 |